Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03950752
Other study ID # PALMFREE
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 19, 2019
Est. completion date November 8, 2019

Study information

Verified date March 2022
Source Technological Centre of Nutrition and Health, Spain
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Postprandial lipemia produced by fat intake is a major risk factor for the development of cardiovascular diseases (CVD), the most important cause of disease and death in the Western world. Scientific evidence shows that the consumption of saturated fatty acids has a potential harmful effect on postprandial lipemia compared to the intake of monounsaturated fatty acids. The magnitude of postprandial lipemia is also determined by the health status of individuals, being altered in individuals with metabolic disorders associated with the development of CVD, such as hypertriglyceridemia. Palm oil is widely used in bakery products because it is more economical compared to other fats and oils of other origin and for its stability properties that contribute to this type of food. This oil has a profile of fatty acids, rich in saturated fatty acids, mainly palmitic acid, which as mentioned above, is associated with health alterations. In addition, the investigators must add the environmental problems that are generated by the massive cultivation of the plant from which palm oil is extracted (oil palm Elaeis guineensis), including the loss of thousands of hectares of tropical forest and endangering to dozens of animal species from deforested areas. The proliferation of all these arguments associated with the effect on the health and environment of the consumption of palm oil has given way to a paradigm shift in the use of palm oil in the food sector. The hypothesis of the study is that consumption of bagels with a composition optimized in fatty acids, eliminating the content of palm oil and replacing it with high oleic sunflower oil and stearic acid completely hydrogenated without trans fatty acids, so that the same amount of fat is maintained, will decrease the postprandial lipemia, compared to the consumption of bagels with a more conventional composition in fatty acids, in healthy and / or with mild-moderate hypertriglyceridemia individuals. The main objective of this study was to evaluate the effect of acute consumption of bagels without palm oil in its formulation and with an optimized fatty acid composition on postprandial lipemia measuring the evolution of plasma triglyceride levels in healthy and/or with mild-moderated hypertriglyceridemia individuals.


Recruitment information / eligibility

Status Completed
Enrollment 41
Est. completion date November 8, 2019
Est. primary completion date November 8, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria healthy population: 1. Men and women over 18 years of age. 2. Sign the informed consent. 3. Fasting serum triglyceride concentration < 150 mg/dL. Exclusion Criteria healthy population: 1. Having diabetes (glucose = 126 mg/dL). 2. BMI values <18 kg/m^2 o >25 kg/m^2. 3. Waist circumference > 150 cm. 4. Present dyslipidemia (LDL cholesterol > 189 mg/dL). 5. Present celiac disease or food allergies related to the study product. 6. Presenting anemia (hemoglobin = 13 g/dL in men and = 12 g/dL in women). 7. Being pregnant or intending to become pregnant. 8. Be in breastfeeding period. 9. Participate in or have participated in a clinical trial or nutritional intervention study in the last 30 days prior to inclusion in the study. 10. Follow a hypocaloric diet and/or pharmacological treatment for weight loss. Inclusion Criteria mild-moderated hypertriglyceridemia population: 1. Men and women over 18 years of age. 2. Sign the informed consent. 3. Fasting serum triglyceride concentration = 150 mg/dL. Exclusion Criteria mild-moderated hypertriglyceridemia population: 1. Having diabetes (glucose = 126 mg/dL). 2. Fasting serum triglyceride concentration > 880 mg/dL. 3. History of pancreatitis. 4. Serum LDL cholesterol levels > 189 mg/dL). 5. Present celiac disease or food allergies related to the study product. 6. Presenting anemia (hemoglobin = 13 g/dL in men and = 12 g/dL in women). 7. Being pregnant or intending to become pregnant. 8. Be in breastfeeding period. 9. Participate in or have participated in a clinical trial or nutritional intervention study in the last 30 days prior to inclusion in the study. 10. Follow a hypocaloric diet and/or pharmacological treatment for weight loss.

Study Design


Related Conditions & MeSH terms


Intervention

Combination Product:
Optimized Bagel
Participants will eat 132g of a bagel with an optimized composition in fatty acids in only one day, representing an ingestion of 556.5 kcal and 33g of total fat, of which 4.41g are saturated fatty acids, 24.27g are monounsaturated fatty acids, and 4.28g are polyunsaturated fatty acids.
Conventional Bagel
Participants will eat 132g of a bagel with a conventional composition in fatty acids in only one day, representing an ingestion of 589.0 kcal and 35.6g of total fat, of which 16.76g are saturated fatty acids, 13.00g are monounsaturated fatty acids, and 5.81g are polyunsaturated fatty acids

Locations

Country Name City State
Spain Centro Tecnológico de Nutrición y Salud (Eurecat-Reus) Reus Tarragona

Sponsors (4)

Lead Sponsor Collaborator
Technological Centre of Nutrition and Health, Spain Europastry S.A., Fundació Eurecat, Hospital Universitari Sant Joan de Reus

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Postprandial triglycerides levels Evolution of postprandial triglycerides levels in blood, assessed as area under the curve (AUC).
Serum triglycerides levels will be measured by standardized methods in a Cobas Mira Plus autoanalyzer (Roche Diagnostics Systems, Madrid, Spain).
Triglyceride levels in plasma will be determined before consuming bagels and after ingestion of bagels at 30 minutes, 1 hour, 2 hours, 4 hours and 6 hours at Visit 1 and Visit 2.
Secondary Changes in endothelial function Measurement of the endothelial function using the Laser-Doppler technique. Endothelial function will be measured at 4 hours after the consumption of bagels at Visit 1 ad Visit 2.
Secondary Changes in blood pressure (measured in mmHg) Systolic and diastolic blood pressure (SBP and DBP) will be measured twice after 2-5 minutes of patient respite, seated, with one-minute interval in between, using an automatic sphygmomanometer (OMRON HEM-907; Peroxfarma, Barcelona, Spain). Blood pressure will be measured before consuming bagels and at 4 hours after the consumption of bagels at Visit 1 and Visit 2.
Secondary Evolution of postprandial glucose and insulin levels Evolution of postprandial glucose and insulin levels in blood. It will be measured as AUC.
Serum glucose and insulin levels will be measured by standardized methods in a Cobas Mira Plus autoanalyzer (Roche Diagnostics Systems, Madrid, Spain).
Glucose and insulin plasma levels will be determined before consuming bagels and at 30 minutes, 1 hour, 2 hours and 4 hours after the consumption of bagels at Visit 1 and Visit 2.
Secondary Evolution of postprandial non-esterified fatty acids, total cholesterol, LDL and HDL cholesterol blood levels. Evolution of non-esterified fatty acids, total cholesterol, LDL and HDL cholesterol in blood after the consumption of bagels.
Serum parameters will be measured by standardized methods in a Cobas Mira Plus autoanalyzer (Roche Diagnostics Systems, Madrid, Spain).
Non-esterified fatty acids, total cholesterol, LDL and HDL cholesterol plasma levels will be determined before consuming bagels and at 1 hour, 2 hours, 4 hours and 6 hours after the consumption of bagels at Visit 1 and Visit 2.
Secondary Evolution of postprandial Apolipoprotein (Apo) B-48, Apo B100 and Apo A1 in blood. Evolution of Apo B48, Apo B100 and Apo A1 in blood after the consumption of bagels.
Apo B100 and Apo A1 in serum will be measured by standardized methods in a Cobas Mira Plus autoanalyzer (Roche Diagnostics Systems, Madrid, Spain). Apo B48 in serum will be measured by an ELISA kit.
Apo B48, Apo B100 and Apo A1 plasma levels will be determined before consuming bagels and at 4 hours and 6 hours after the consumption of bagels at Visit 1 and Visit 2.
Secondary Evolution of postprandial levels in blood of inflammation, thrombosis and oxidative stress markers in blood. Evolution of the inflammation markers Interleukin 6 (IL-6), E-selectin, Intercellular adhesion molecule-1 (ICAM) and Vascular cellular adhesion molecule-1 (VCAM), the thrombosis markers Plasminogen activator 1 (PA-1) and Thrombomodulin, and the oxidative stress markers Oxygen Radical Absorbance Capacity (ORAC) and Malondialdehyde.
Serum parameters will be measured by human ELISA kits.
IL-6, E-selectin, ICAM, VCAM, PA-1, Thrombomodulin and ORAC plasma levels will be determined before consuming bagels and at 4 hours and 6 hours after the consumption of bagels at Visit 1 and Visit 2.
Secondary Evolution of postprandial lipoprotein lipase activity in blood. Evolution of postprandial activity levels of lipoprotein lipase (LPL) in blood. It will measured by a fluorometric kit.
Serum activity of LPL will be measured by an fluorometric kit.
LPL activity levels in plasma wil be measurd before consuming bagels and at 4 hours and 6 hours after the consumption of bagels at Visit 1 and Visit 2.
Secondary Fatty acid composition of postprandial serum triglycerides levels in blood. Evaluation of fatty acid composition of serum triglycerides in blood. It will be measured by liquid chromatography coupled to mass spectrometry. Fatty acid composition of serum triglycerides will be measured before consuming bagels and at 6 hours after the consumption of bagels at Visit 1 and Visit 2.
See also
  Status Clinical Trial Phase
Completed NCT04382521 - A Text Message Intervention to Promote Health Behaviors in Cardiac Risk Conditions N/A
Not yet recruiting NCT02593487 - Effect of Rosuvastatin Therapy on HDL2 Level Phase 4
Active, not recruiting NCT02697422 - Veteran Peer Coaches Optimizing and Advancing Cardiac Health N/A
Completed NCT04469673 - A Study to Evaluate the Safety, Tolerability and Efficacy of Multiple Doses of JS002 in Patients With Hyperlipidemia.. Phase 1/Phase 2
Recruiting NCT05912296 - A Single and Multiple Ascending Doses Study to Evaluate the Safety, Tolerability and Pharmacokinetics of RBD7022 Phase 1
Active, not recruiting NCT05432544 - Safety and Tolerability of SHR-1918 in Healthy Subjects Phase 1
Not yet recruiting NCT06229548 - A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2053 Phase 1
Completed NCT05532800 - The Efficacy and Safety of JS002 PFS and AI in Patients With Primary Hypercholesterolemia and Mixed Hyperlipidemia Phase 3
Completed NCT04781114 - The Safety and Efficacy of Multiple-dose of JS002 in Subject With Hyperlipidemia Phase 3
Active, not recruiting NCT04515927 - To Evaluate the Efficacy and Safety of JS002 in HoFH Patients Phase 2